195 related articles for article (PubMed ID: 21616994)
1. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Staff AC; Trovik J; Eriksson AG; Wik E; Wollert KC; Kempf T; Salvesen HB
Clin Cancer Res; 2011 Jul; 17(14):4825-33. PubMed ID: 21616994
[TBL] [Abstract][Full Text] [Related]
2. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
[TBL] [Abstract][Full Text] [Related]
3. Plasma calprotectin concentrations in women with endometrial carcinoma.
Ni Bhriain H; Trovik J; Wik E; Stefansson IM; Akslen LA; Salvesen HB; Staff AC
Gynecol Oncol; 2009 Sep; 114(3):491-5. PubMed ID: 19577278
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Staff AC; Bock AJ; Becker C; Kempf T; Wollert KC; Davidson B
Gynecol Oncol; 2010 Sep; 118(3):237-43. PubMed ID: 20576287
[TBL] [Abstract][Full Text] [Related]
5. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
6. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
7. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
Ivanov I
Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
9. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.
Coleman RL; Schink JC; Miller DS; Bauer KD; August CZ; Rademaker AW; Lurain JR
Gynecol Oncol; 1993 Jul; 50(1):20-4. PubMed ID: 8349159
[TBL] [Abstract][Full Text] [Related]
10. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
Engerud H; Hope K; Berg HF; Fasmer KE; Tangen IL; Haldorsen IS; Trovik J; Krakstad C
PLoS One; 2019; 14(1):e0210585. PubMed ID: 30645608
[TBL] [Abstract][Full Text] [Related]
11. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
Fujimoto T; Nanjyo H; Nakamura A; Yokoyama Y; Takano T; Shoji T; Nakahara K; Yamada H; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
Gynecol Oncol; 2007 Nov; 107(2):253-9. PubMed ID: 17640720
[TBL] [Abstract][Full Text] [Related]
12. Lymph node sampling and survival in endometrial cancer.
Trimble EL; Kosary C; Park RC
Gynecol Oncol; 1998 Dec; 71(3):340-3. PubMed ID: 9887227
[TBL] [Abstract][Full Text] [Related]
13. Use of the sentinel node procedure to stage endometrial cancer.
Ballester M; Dubernard G; Rouzier R; Barranger E; Darai E
Ann Surg Oncol; 2008 May; 15(5):1523-9. PubMed ID: 18322758
[TBL] [Abstract][Full Text] [Related]
14. Analysis of FIGO Stage IIIc endometrial cancer patients.
McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor-15 as biomarker in uterine sarcomas.
Trovik J; Salvesen HB; Cuppens T; Amant F; Staff AC
Int J Gynecol Cancer; 2014 Feb; 24(2):252-9. PubMed ID: 24401984
[TBL] [Abstract][Full Text] [Related]
16. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer.
Chen YL; Huang CY; Chien TY; Huang SH; Wu CJ; Ho CM
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):397-402. PubMed ID: 21806586
[TBL] [Abstract][Full Text] [Related]
17. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors in diagnosed endometrial cancers determining the type of radical surgery].
Ivanov S; Tomov S
Akush Ginekol (Sofiia); 2009; 48(3):14-9. PubMed ID: 20198758
[TBL] [Abstract][Full Text] [Related]
19. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.
Briët JM; Hollema H; Reesink N; Aalders JG; Mourits MJ; ten Hoor KA; Pras E; Boezen HM; van der Zee AG; Nijman HW
Gynecol Oncol; 2005 Mar; 96(3):799-804. PubMed ID: 15721428
[TBL] [Abstract][Full Text] [Related]
20. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
